Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
about
Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling)Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer?Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationHEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity.Current status and perspectives of patient-derived xenograft models in cancer research.Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsA new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.Immunooncology: Can the Right Chimeric Antigen Receptors T-Cell Design Be Made to Cure All Types of Cancers and Will It Be Covered?New development in CAR-T cell therapy.Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry studyT cell optimization for the treatment of pancreatic cancer.Reconstructing the immune system with lentiviral vectors.Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy.The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.Driving gene-engineered T cell immunotherapy of cancer.Tumor-targeting domains for chimeric antigen receptor T cells.The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy.Neoepitopes as cancer immunotherapy targets: key challenges and opportunities.CAR T-cell therapy for pancreatic cancer.Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.The retroviral vector family: something for everyone.DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy.The interdomain flexible linker of the polypeptide GalNAc transferases dictates their long-range glycosylation preferences.Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination.Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?Emerging trends in the immunotherapy of pancreatic cancer.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy.Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy.Redirecting Killer T Cells through Incorporation of Azido Sugars for Tethering Ligands.Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
P2860
Q26739942-5814CA08-1D21-4B61-B196-EA85A7ED0C9FQ26741977-DF75BB7E-6980-454E-8FFF-7859E02232C1Q28068378-9AB91615-D238-49F7-BF00-11D73FF2E855Q30843463-6B341AA7-0080-4DF8-90D4-097777ECE11DQ33641923-3DE5CDDA-7C9D-411C-80B4-F0002BE39BD0Q33667686-294F722B-E046-4A25-8A56-5EE1350A78E3Q33833475-37D302C2-3DCB-447F-A47F-5EA2B009DF8FQ37555940-F4977914-FAC5-4365-ABA6-AD86816A592CQ37559401-FC233608-EFB8-44A7-A696-16DE237EF089Q37587362-742116EB-6826-4E85-A7A1-647E2A65D1C5Q37625303-CF9205B8-C196-4BB7-ACB0-DF5F5D9F1F33Q37658246-713D3352-EA22-4524-B569-6644B0DC0635Q37706835-580B90A4-014E-48C4-A9E9-39B1D1E4AEA3Q37747899-F02687B1-1F09-45CC-AB5F-53C1ADC9006BQ38638035-0D7E5498-7EFD-43BD-8C13-1D9BFC4F30DAQ38651711-4C37314C-6C81-498A-9159-CD8D045AAB46Q38656009-6DAA4E67-F51E-4A25-B644-32A3AFAFF8FEQ38748836-BC212619-0A40-45AE-A528-7608339A5C3CQ38777742-638E47C7-64D1-45F1-ACAB-29F7496EEB42Q39045535-2217EE4E-9286-466C-8549-E1A5A86FE05AQ39115858-A80B6D45-B54C-4529-8F8D-3B2C1AE33CEDQ39183391-07EBD6D8-3A2A-4C37-AB82-122190219812Q39202440-F7835CB3-F412-4AC1-875C-A638B42E79E2Q39256918-5C9F314B-7E33-4E46-B2CC-18D6AC57A3B0Q39280002-E41574FF-6DAE-4067-9CD6-FBB4CFFD7714Q39359422-6ED2E046-2C99-42F2-A4EA-8568440E3209Q40095245-C501FBB4-D908-442E-B7E1-8CF836FB3647Q40100053-116504CA-B1F6-4A9E-9D6C-53CADB7FA6DFQ41764893-F8244345-93F3-4CAD-ABB8-552B6A4C7688Q47116819-A13856EA-4E03-40EC-915F-3AD3A2ED2614Q47201342-4B9DB139-A26F-43B3-B873-6CCA3D1BB371Q47209071-3EF059B4-E986-4928-8006-D60B39A9CACFQ47221163-D1FD3F51-60A5-4951-A584-9E6B6557F2EDQ47248817-87764430-A312-40F9-B33E-D3758D80D7B2Q47285613-1F3C281E-D5AC-4E46-9CD6-AD125D2A13ACQ47438165-E2C97E64-C76F-4793-A7CC-A2AB4C0D87ADQ47568391-22C805AA-76A5-46B1-AD43-CA54E3749513Q47726467-DA4C1A98-86DD-4886-A320-766F1B002FC8Q47729518-5D69F830-9183-4905-A90B-3084F3875476Q47843897-8F576D43-C9E7-4F12-B673-24667221877A
P2860
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Engineered CAR T Cells Targeti ...... in MUC1 Control Adenocarcinoma
@en
Engineered CAR T Cells Targeti ...... n MUC1 Control Adenocarcinoma.
@nl
type
label
Engineered CAR T Cells Targeti ...... in MUC1 Control Adenocarcinoma
@en
Engineered CAR T Cells Targeti ...... n MUC1 Control Adenocarcinoma.
@nl
prefLabel
Engineered CAR T Cells Targeti ...... in MUC1 Control Adenocarcinoma
@en
Engineered CAR T Cells Targeti ...... n MUC1 Control Adenocarcinoma.
@nl
P2093
P2860
P50
P1433
P1476
Engineered CAR T Cells Targeti ...... in MUC1 Control Adenocarcinoma
@en
P2093
Alina C Boesteanu
Avery D Posey
Boris Engels
Brian Keith
Carl H June
David M Kranz
Decheng Song
Hans Schreiber
Henrik Clausen
Jennifer D Stone
P2860
P304
P356
10.1016/J.IMMUNI.2016.05.014
P407
P577
2016-06-01T00:00:00Z